{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T16:59:52Z","timestamp":1760979592191,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.bmcl.2004.05.012","type":"journal-article","created":{"date-parts":[[2004,6,8]],"date-time":"2004-06-08T14:49:43Z","timestamp":1086706183000},"page":"3679-3681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Novel \u03b42-isoxazolines as group II phospholipase A2 inhibitors"],"prefix":"10.1016","volume":"14","author":[{"family":"Basappa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Satish Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Nanjunda Swamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Mahendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Shashidhara Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.S","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.S","family":"Rangappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2004.05.012_BIB1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0014-2999(96)00257-9","volume":"308","author":"Fox","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bmcl.2004.05.012_BIB2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1054-3589(08)61011-X","volume":"32","author":"Glaser","year":"1995","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.bmcl.2004.05.012_BIB3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1096\/fasebj.7.2.8440410","volume":"7","author":"Mayer","year":"1993","journal-title":"FASEB J."},{"key":"10.1016\/j.bmcl.2004.05.012_reference0020","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/BF00914317","volume":"12","author":"Vishwanath","year":"1988","journal-title":"Inflammation"},{"key":"10.1016\/j.bmcl.2004.05.012_reference0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jmb.2003.08.032","volume":"333","author":"Sekar","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bmcl.2004.05.012_BIB5","unstructured":"Manjunath Kini, R. Venom Phospholipase A2 enzymes. In: Structure, Function and Mechanism; John Wiley and Sons: England, 1997"},{"issue":"308","key":"10.1016\/j.bmcl.2004.05.012_BIB6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/bj3080297","volume":"7","author":"Fujii","year":"1995","journal-title":"Biochem. J."},{"key":"10.1016\/j.bmcl.2004.05.012_BIB7","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1021\/jm0101287","volume":"44","author":"Amgad","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmcl.2004.05.012_reference0040","first-page":"163","volume":"38","author":"Ravikumar","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmcl.2004.05.012_reference0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ardp.200390015","volume":"336","author":"Ravikumar","year":"2003","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bmcl.2004.05.012_BIB9","first-page":"31","author":"Beeranahally Doreswamy","year":"2003","journal-title":"Anal. Sci."},{"key":"10.1016\/j.bmcl.2004.05.012_BIB10","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1016\/j.bmc.2003.08.007","volume":"11","author":"Basappa","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmcl.2004.05.012_reference0060","first-page":"337","volume":"Vol. 1","author":"Caramella","year":"1984"},{"key":"10.1016\/j.bmcl.2004.05.012_reference0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/anie.196305651","volume":"2","author":"Huisgen","year":"1963","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.bmcl.2004.05.012_BIB13A","unstructured":"PLA2 activity: Assayed with [14C] oleate-labeled autoclaved E. coli as the substrate. The reaction mixture, 350\u03bcL contained 100mM Tris\/HCl, pH8.0, 5mM Ca2+, and 3.15\u00d7109 autoclaved E. coli cells (corresponding to 10,000cpm and 60nmol of lipid phosphorous). The amount of enzyme protein was chosen such that 10\u201315% hydrolysis of substrate was obtained when incubated at 37\u00b0C for 60min. The reaction components were mixed in the following order: buffer, calcium, water, and \u03b42-isoxazoline derivatives. Adding labeled E. coli substrate started the reaction. The reaction was terminated by adding 100\u03bcL of 2.0M HCl, and 100\u03bcL of fatty acid free BSA (100mg\/mL). The tubes were vortex mixed and centrifuged at 20,000g for 5min. Aliquot (140\u03bcL) of the supernatant containing released [14C] oleic acid was mixed with scintillation cocktail 13 and counted in a Hewlett Packard liquid Scintillation Analyzer TRI CARB 2100 TR"},{"key":"10.1016\/j.bmcl.2004.05.012_BIB13B","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI116791","volume":"92","author":"Vishwanath","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bmcl.2004.05.012_BIB13C","unstructured":"Determination of edema inducing activity: Groups of six mice (22\u201324g) were injected in the right footpads of hind limbs with 3mM dose of \u03b42-isoxazolines in 20\u03bcL saline. The left footpads received 20\u03bcL of saline, which served as control. After 45min, mice were sacrificed by cervical dislocation and both legs were cut at the ankle joint and weighed individually. The increase in weight due to edema was calculated as the edema ratio, which equals the weight of edematous leg\u00d7100\/weight of the normal leg minimum edema dose, is defined as the microgram of protein causing an edema ration of 120%. Edema ratio=weight of edematous leg\u00d7100\/weight of normal leg"},{"key":"10.1016\/j.bmcl.2004.05.012_BIB14","first-page":"307","article-title":"Processing of X-ray Diffraction Data Collected in Oscillation mode","volume":"Vol. 276","author":"Otwinowski","year":"1997"},{"key":"10.1016\/j.bmcl.2004.05.012_BIB15","unstructured":"Sheldrick, G.M. shelx-97; University of G\u00f6ttingen, G\u00f6ttingen, Germany, 1997"},{"key":"10.1016\/j.bmcl.2004.05.012_BIB16","unstructured":"Johnson, C.K. ORTEP-II. A Fortran Thermal-Ellipsoid Plot Program. Report ORNL-5138; Oak Ridge National Laboratory, Oak Ridge, TN, USA, 1976"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X04006456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X04006456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T05:27:28Z","timestamp":1760765248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X04006456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":20,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0960894X04006456"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2004.05.012","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2004,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel \u03b42-isoxazolines as group II phospholipase A2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2004.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}